Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
bullseye rash in the arm where Shingrix was administered; Injection site pain; Redness; This non-serious case was reported by a physician via sales rep and described the occurrence of injection site rash in a patient who received Herpes zoster (Shingrix) for an unknown indication. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site rash (Verbatim: bullseye rash in the arm where Shingrix was administered), injection site pain (Verbatim: Injection site pain) and injection site erythema (Verbatim: Redness). The action taken with Shingrix was unknown. The outcome of the injection site rash, injection site pain and injection site erythema were unknown. It was unknown if the reporter considered the injection site rash, injection site pain and injection site erythema to be related to Shingrix. It was unknown if the company considered the injection site rash, injection site pain and injection site erythema to be related to Shingrix. Additional Information: GSK receipt date: 20-MAR-2025 Physician stated that a patient experienced bullseye rash in the arm where Shingrix was administered. Reporter asked if the patient get the second shot if their first reaction was painful, redness, and a bullseye effect or not.